Impact of smoking on dendritic cell phenotypes in the airway lumen of patients with COPD

Respiratory Research

Marek Lommatzsch¹  J Christian Virchow¹  Michael Kuepper¹  Katharina Garbe¹  Andrea Bier¹  Kai Bratke¹  Ann-Sophie Heinz¹  Paul Stoll¹ 

[1] Department of Pneumology and Critical Care Medicine, University of Rostock, Ernst-Heydemann-Str. 6, 18057 Rostock, Germany

关键词: Airway;    Smoking;    COPD;    Dendritic cells;   

Others  :  790322
DOI  :  10.1186/1465-9921-15-48

 received in 2013-11-11, accepted in 2014-04-11,  发布年份 2014

【 摘 要 】

Background

Myeloid dendritic cells (DCs) are increased in the airway wall of patients with chronic obstructive pulmonary disease (COPD), and postulated to play a crucial role in COPD. However, DC phenotypes in COPD are poorly understood.

Methods

Function-associated surface molecules on bronchoalveolar lavage fluid (BALF) DCs were analyzed using flow cytometry in current smokers with COPD, in former smokers with COPD and in never-smoking controls.

Results

Myeloid DCs of current smokers with COPD displayed a significantly increased expression of receptors for antigen recognition such as BDCA-1 or Langerin, as compared with never-smoking controls. In contrast, former smokers with COPD displayed a significantly decreased expression of these receptors, as compared with never-smoking controls. A significantly reduced expression of the maturation marker CD83 on myeloid DCs was found in current smokers with COPD, but not in former smokers with COPD. The chemokine receptor CCR5 on myeloid DCs, which is also important for the uptake and procession of microbial antigens, was strongly reduced in all patients with COPD, independently of the smoking status.

Conclusion

COPD is characterized by a strongly reduced CCR5 expression on myeloid DCs in the airway lumen, which might hamper DC interactions with microbial antigens. Further studies are needed to better understand the role of CCR5 in the pathophysiology and microbiology of COPD.

【 授权许可】

   
2014 Stoll et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Brusselle GG, Joos GF, Bracke KR: New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011, 378:1015-1026.
• [2]Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD: The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:2645-2653.
• [3]Tsoumakidou M, Demedts IK, Brusselle GG, Jeffery PK: Dendritic cells in chronic obstructive pulmonary disease: new players in an old game. Am J Respir Crit Care Med 2008, 177:1180-1186.
• [4]Brusselle GG, Demoor T, Bracke KR, Brandsma CA, Timens W: Lymphoid follicles in (very) severe COPD: beneficial or harmful? Eur Respir J 2009, 34:219-230.
• [5]Cosio MG, Saetta M, Agusti A: Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009, 360:2445-2454.
• [6]Tzortzaki EG, Siafakas NM: A hypothesis for the initiation of COPD. Eur Respir J 2009, 34:310-315.
• [7]Demedts IK, Bracke KR, Van Pottelberge G, Testelmans D, Verleden GM, Vermassen FE, Joos GF, Brusselle GG: Accumulation of dendritic cells and increased CCL20 levels in the airways of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175:998-1005.
• [8]Van Pottelberge GR, Bracke KR, Demedts IK, De Rijck K, Reinartz SM, van Drunen CM, Verleden GM, Vermassen FE, Joos GF, Brusselle GG: Selective accumulation of langerhans-type dendritic cells in small airways of patients with COPD. Respir Res 2010, 11:35. BioMed Central Full Text
• [9]Vassallo R, Walters PR, Lamont J, Kottom TJ, Yi ES, Limper AH: Cigarette smoke promotes dendritic cell accumulation in COPD; a Lung Tissue Research Consortium study. Respir Res 2010, 11:45. BioMed Central Full Text
• [10]Mori M, Andersson CK, Svedberg KA, Glader P, Bergqvist A, Shikhagaie M, Lofdahl CG, Erjefalt JS: Appearance of remodelled and dendritic cell-rich alveolar-lymphoid interfaces provides a structural basis for increased alveolar antigen uptake in chronic obstructive pulmonary disease. Thorax 2013, 68:521-531.
• [11]Freeman CM, Martinez FJ, Han MK, Ames TM, Chensue SW, Todt JC, Arenberg DA, Meldrum CA, Getty C, McCloskey L, Curtis JL: Lung dendritic cell expression of maturation molecules increases with worsening chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 180:1179-1188.
• [12]Tsoumakidou M, Koutsopoulos AV, Tzanakis N, Dambaki K, Tzortzaki E, Zakynthinos S, Jeffery PK, Siafakas NM: Decreased small airway and alveolar CD83+ dendritic cells in COPD. Chest 2009, 136:726-733.
• [13]Bratke K, Lommatzsch M, Julius P, Kuepper M, Kleine HD, Luttmann W, Christian Virchow J: Dendritic cell subsets in human bronchoalveolar lavage fluid after segmental allergen challenge. Thorax 2007, 62:168-175.
• [14]Bratke K, Klug M, Bier A, Julius P, Kuepper M, Virchow JC, Lommatzsch M: Function-associated surface molecules on airway dendritic cells in cigarette smokers. Am J Respir Cell Mol Biol 2008, 38:655-660.
• [15]Lommatzsch M, Bratke K, Bier A, Julius P, Kuepper M, Luttmann W, Virchow JC: Airway dendritic cell phenotypes in inflammatory diseases of the human lung. Eur Respir J 2007, 30:878-886.
• [16]Lommatzsch M, Bratke K, Knappe T, Bier A, Dreschler K, Kuepper M, Stoll P, Julius P, Virchow JC: Acute effects of tobacco smoke on human airway dendritic cells in vivo. Eur Respir J 2010, 35:1130-1136.
• [17]Aquino A, Graziani G, Franzese O, Prete SP, Bonmassar E, Bonmassar L, D'Atri S: Exogenous control of the expression of Group I CD1 molecules competent for presentation of microbial nonpeptide antigens to human T lymphocytes. Clin Dev Immunol 2011, 2011:790460.
• [18]van der Vlist M, Geijtenbeek TB: Langerin functions as an antiviral receptor on Langerhans cells. Immunol Cell Biol 2010, 88:410-415.
• [19]Martinez-Pomares L: The mannose receptor. J Leukoc Biol 2012, 92:1177-1186.
• [20]Tordjman R, Lepelletier Y, Lemarchandel V, Cambot M, Gaulard P, Hermine O, Romeo PH: A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response. Nat Immunol 2002, 3:477-482.
• [21]Bakdash G, Sittig SP, van Dijk T, Figdor CG, de Vries IJ: The nature of activatory and tolerogenic dendritic cell-derived signal II. Front Immunol 2013, 4:53.
• [22]Morser J: Thrombomodulin links coagulation to inflammation and immunity. Curr Drug Targets 2012, 13:421-431.
• [23]Prechtel AT, Steinkasserer A: CD83: an update on functions and prospects of the maturation marker of dendritic cells. Arch Dermatol Res 2007, 299:59-69.
• [24]Dreschler K, Bratke K, Petermann S, Bier A, Thamm P, Kuepper M, Virchow JC, Lommatzsch M: Impact of immunotherapy on blood dendritic cells in patients with Hymenoptera venom allergy. J Allergy Clin Immunol 2011, 127:487-494. e481-483
• [25]Segura E, Touzot M, Bohineust A, Cappuccio A, Chiocchia G, Hosmalin A, Dalod M, Soumelis V, Amigorena S: Human inflammatory dendritic cells induce Th17 cell differentiation. Immunity 2013, 38:336-348.
• [26]Tsoumakidou M, Elston W, Zhu J, Wang Z, Gamble E, Siafakas NM, Barnes NC, Jeffery PK: Cigarette smoking alters bronchial mucosal immunity in asthma. Am J Respir Crit Care Med 2007, 175:919-925.
• [27]Tsoumakidou M, Jeffery PK: Dendritic cell maturity and obstructive airway disease. Am J Respir Crit Care Med 2007, 176:833. author reply 833-834.
• [28]Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, Horuk R, Sparre-Ulrich AH, Locati M, Luster AD, Mantovani A, Matsushima K, Murphy PM, Nibbs R, Nomiyama H, Power CA, Proudfoot AE, Rosenkilde MM, Rot A, Sozzani S, Thelen M, Yoshie O, Zlotnik A: International Union of Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev 2014, 66:1-79.
• [29]Alonzo F 3rd, Kozhaya L, Rawlings SA, Reyes-Robles T, DuMont AL, Myszka DG, Landau NR, Unutmaz D, Torres VJ: CCR5 is a receptor for Staphylococcus aureus leukotoxin ED. Nature 2013, 493:51-55.
• [30]Cameron PU, Handley AJ, Baylis DC, Solomon AE, Bernard N, Purcell DF, Lewin SR: Preferential infection of dendritic cells during human immunodeficiency virus type 1 infection of blood leukocytes. J Virol 2007, 81:2297-2306.
• [31]Henrich TJ, Kuritzkes DR: HIV-1 entry inhibitors: recent development and clinical use. Curr Opin Virol 2013, 3:51-57.
• [32]Floto RA, MacAry PA, Boname JM, Mien TS, Kampmann B, Hair JR, Huey OS, Houben EN, Pieters J, Day C, Oehlmann W, Singh M, Smith KG, Lehner PJ: Dendritic cell stimulation by mycobacterial Hsp70 is mediated through CCR5. Science 2006, 314:454-458.
• [33]Dawson TC, Beck MA, Kuziel WA, Henderson F, Maeda N: Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus. Am J Pathol 2000, 156:1951-1959.
• [34]Glass WG, McDermott DH, Lim JK, Lekhong S, Yu SF, Frank WA, Pape J, Cheshier RC, Murphy PM: CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006, 203:35-40.
• [35]Kindberg E, Mickiene A, Ax C, Akerlind B, Vene S, Lindquist L, Lundkvist A, Svensson L: A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J Infect Dis 2008, 197:266-269.
• [36]Keynan Y, Juno J, Meyers A, Ball TB, Kumar A, Rubinstein E, Fowke KR: Chemokine receptor 5 Δ32 allele in patients with severe pandemic (H1N1) 2009. Emerg Infect Dis 2010, 16:1621-1622.
• [37]Rodriguez A, Falcon A, Cuevas MT, Pozo F, Guerra S, Garcia-Barreno B, Martinez-Orellana P, Perez-Brena P, Montoya M, Melero JA, Pizarro M, Ortin J, Casas I, Nieto A: Characterization in vitro and in vivo of a pandemic H1N1 influenza virus from a fatal case. PLoS One 2013, 8:e53515.
• [38]Bracke KR, D'Hulst AI, Maes T, Demedts IK, Moerloose KB, Kuziel WA, Joos GF, Brusselle GG: Cigarette smoke-induced pulmonary inflammation, but not airway remodelling, is attenuated in chemokine receptor 5-deficient mice. Clin Exp Allergy 2007, 37:1467-1479.
• [39]Freeman CM, Curtis JL, Chensue SW: CC chemokine receptor 5 and CXC chemokine receptor 6 expression by lung CD8+ cells correlates with chronic obstructive pulmonary disease severity. Am J Pathol 2007, 171:767-776.
• [40]Bracke KR, Demedts IK, Joos GF, Brusselle GG: CC-chemokine receptors in chronic obstructive pulmonary disease. Inflamm Allergy Drug Targets 2007, 6:75-79.
• [41]Barnes NC, Qiu YS, Pavord ID, Parker D, Davis PA, Zhu J, Johnson M, Thomson NC, Jeffery PK: Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006, 173:736-743.
• [42]Bourbeau J, Christodoulopoulos P, Maltais F, Yamauchi Y, Olivenstein R, Hamid Q: Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 2007, 62:938-943.
• [43]Rossios C, To Y, Osoata G, Ito M, Barnes PJ, Ito K: Corticosteroid insensitivity is reversed by formoterol via phosphoinositide-3-kinase inhibition. Br J Pharmacol 2012, 167:775-786.
• [44]Lommatzsch M, Kraeft U, Troebs L, Garbe K, Bier A, Stoll P, Klammt S, Kuepper M, Bratke K, Virchow JC: Fluticasone impact on airway dendritic cells in smokers: a randomized controlled trial. Respir Res 2013, 14:114. BioMed Central Full Text
• [45]Van Pottelberge GR, Bracke KR, Van den Broeck S, Reinartz SM, van Drunen CM, Wouters EF, Verleden GM, Vermassen FE, Joos GF, Brusselle GG: Plasmacytoid dendritic cells in pulmonary lymphoid follicles of patients with COPD. Eur Respir J 2010, 36:781-791.